Brown & Brown (BRO) is down sharply in Thursday trading as investors digest the company’s first-quarter 2026 results and call commentary, which highlighted strong headline growth but weak underlying momentum. Total revenue rose to about $1.9 billion, but organic revenue growth was flat (or only modestly positive when including contingents), a combination that can signal that acquisitions—not core demand—are doing most of the heavy lifting. (investor.bbrown.com)

The quarter featured an adjusted EPS figure of $1.39 and an adjusted EBITDA margin around 38.5%, which were not the problem on their own; the market reaction appears driven by the quality of growth and the sustainability of margins as the company integrates Accession and continues investing. Management’s materials also pointed to segment-level organic growth that varied, including Retail being affected by a change in revenue model at a pharmacy consulting business. (benzinga.com)

Insurance brokers can trade heavily on organic growth trends and rate environment expectations, not just headline revenue and EPS. With commercial P&C pricing pressure and investor sensitivity to valuation across the space, a quarter showing muted organic growth can overshadow an earnings beat—especially when investors are already cautious about integration execution, synergy timing, and whether acquisition-driven scale converts into durable incremental margins. (investing.com)

Key swing factors for BRO over the next few weeks include updated disclosures around organic growth trajectory, any changes in expense cadence tied to integration, and progress toward expected Accession-related synergy capture. Traders will also watch whether the stock stabilizes after falling near recent lows as the market recalibrates expectations for 2026 organic growth and margin durability. (investing.com)